Reply to Office Action of June 8, 2010

AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of treating a bone or cartilage tissue defect in a

human or other animal subject, comprising the steps of:

(a) culturing endothelial cells in a tissue culture medium to form an endothelial cell tissue

culture;

(b) subjecting said endothelial cell tissue culture to a pulsed electromagnetic field in vitro for

at least about 8 hours delivered at about 4.5 seconds pulses at about 15 Hertz;

(c) extracting said tissue culture medium from said endothelial cell tissue culture; and

(d) administering said tissue culture medium to the site of said bone or cartilage tissue

defect, wherein said administered tissue culture medium enhances proliferation of endothelial cells

and stimulates angiogenesis at said site of the bone or cartilage tissue defect and thereby treating

said bone or cartilage tissue defect.

2. (Cancelled)

3. (Previously Presented) A method according to claim 1 wherein said electromagnetic

field is pulsed.

4. (Cancelled)

Amendment dated December 8, 2010

Reply to Office Action of June 8, 2010

5. (Previously Presented) A method according to claim 1, wherein said bone or

cartilage tissue defect is associated with osteoporosis, spinal fixation procedure, joint replacement

procedure, or bone fracture.

6. (Withdrawn) A method of enhancing cell proliferation in a tissue culture of interest,

comprising the steps of:

(a) culturing a living tissue in a medium to form a first tissue culture;

(b) subjecting said first tissue culture to an electromagnetic field;

(c) extracting said medium from said first tissue culture; and

(d) administering said medium to said tissue culture of interest.

7. (Withdrawn) A method according to claim 6 wherein said electromagnetic field is

pulsed.

8. (Withdrawn) A method according to claim 6 wherein said living tissue comprises

endothelial cells.

9. (Previously Presented) A composition for the treatment of bone or cartilage tissue

defects in a human or other animal subject, comprising a safe and effective amount of a tissue

culture medium produced by pulsed electromagnetic stimulation of an endothelial cell tissue culture

for at least about 8 hours, and a pharmaceutically-acceptable carrier.

Amendment dated December 8, 2010 Reply to Office Action of June 8, 2010

10. (Cancelled)

11. (Cancelled)

12. (Currently Amended) A composition according to claim 9, wherein said carrier is

selected from the group consisting of saline, hyaluronic acid, cellulose ethers (such as

carboxymethyl cellulose), collagen, gelatin, an osteoconductive carrier, and mixtures thereof.

13. (Withdrawn) A composition according to claim 12, wherein said carrier comprises

an osteoconductive carrier selected from the group consisting of bone particles, demineralized bone

matrix, calcium phosphate, calcium sulfate, hydroxyapatite, polylactic acid, polyglycolic acid and

mixtures thereof.

14. (Original) A composition according to claim 9, additionally comprising a growth

active material selected from the group consisting of growth factors, hormones, phosphonates and

mixtures thereof.

15. (Currently Amended) A method of treating a bone or wound defect in a human or

other animal subject, comprising the steps of:

(a) culturing endothelial cells in a tissue culture medium to form a tissue culture;

(b) subjecting said tissue culture to a pulsed electromagnetic field in vitro for at least about 8

hours delivered at about 4.5 seconds pulses at about 15 Hertz;

Application No. 10/522,351 Docket No.: 5490E-000292/US/NPB

Amendment dated December 8, 2010

Reply to Office Action of June 8, 2010

(c) extracting said tissue culture medium from said tissue culture; and

(d) administering said tissue culture medium to the site of said defect,

said tissue culture medium enhancing proliferation of endothelial cells and stimulates

angiogenesis in or near said defect to repair or enhance said tissue defect.

16. (Cancelled)

17. (Withdrawn) The method according to claim 15, wherein said cell type is selected

from the group consisting of osteoblasts, osteocytes, osteoclasts and combinations thereof.

(Cancelled) 18.

19. (Previously Presented) The method according to claim 15, wherein said endothelial

cells comprise human umbilical vein endothelial cells.